ReviewJournal of biochemical and molecular toxicology2026
Extracellular Vesicles in Acute Myeloid Leukemia: Opportunities and Obstacles for Therapeutic Advancement.
Review in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation and blocked maturation of hematopoietic stem and progenitor cells. Despite progress in its clinical management, many patients continue to relapse or show limited response to standard therapies, emphasizing the need for novel, safe, and more effective targeted treatment approaches. In recent years, research has increasingly focused on uncovering the mechanisms responsible for treatment failure to optimize therapeutic strategies. Particular attention has been directed toward the role of extracellular vesicles (EVs) released by AML cells and the ways in which the tumor microenvironment (TME) adapts to promote leukemia progression and survival. Concurrently, advances in biotechnology have led to growing interest in using EVs as therapeutic tools in hematologic malignancies. EVs can function as carriers that induce apoptosis in cancer cells or suppress oncogene expression through their RNA cargo. Therefore, this review aims to synthesize and discuss recent discoveries on the roles and therapeutic potential of EVs in AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.